ABN AMRO Bank N.V. Makes New $83.57 Million Investment in Edwards Lifesciences Corporation $EW

Key Points

• ABN AMRO Bank N.V. acquired 924,314 Edwards Lifesciences shares in the second quarter, valued at approximately $83.6 million and representing about 0.16% of the company. Institutional investors collectively own 79.46% of EW.
• Analysts remain broadly positive, with 17 Buy ratings and six Holds, producing a “Moderate Buy” consensus and an average price target of $100.27. Recent firms raised targets to as high as $110.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS versus a $0.74 consensus and $1.74 billion in revenue, up 13.6% year over year. The stock opened at $91.51, while insiders sold 26,190 shares worth about $2.27 million over the past 90 days.

ABN AMRO Bank N.V. acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 924,314 shares of the medical research company's stock, valued at approximately $83,573,000. ABN AMRO Bank N.V. owned approximately 0.16% of Edwards Lifesciences at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in Edwards Lifesciences by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company's stock worth $9,356,000 after buying an additional 23,514 shares in the last quarter. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $803,686,000. TD Asset Management Inc grew its holdings in shares of Edwards Lifesciences by 6.4% during the 4th quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company's stock valued at $66,335,000 after acquiring an additional 47,051 shares in the last quarter. Intech Investment Management LLC grew its holdings in shares of Edwards Lifesciences by 22.2% during the 4th quarter. Intech Investment Management LLC now owns 69,347 shares of the medical research company's stock valued at $5,912,000 after acquiring an additional 12,591 shares in the last quarter. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $1,626,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

EW has been the subject of several recent research reports. BTIG Research increased their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a research note on Friday, July 24th. Barclays reaffirmed an "overweight" rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the stock a "hold" rating in a research note on Friday, April 24th. Finally, UBS Group began coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They set a "buy" rating and a $110.00 price target for the company. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $100.27.

Insider Activity

In related news, VP Daniel J. Lippis sold 620 shares of the company's stock in a transaction on Monday, May 18th. The shares were sold at an average price of $81.14, for a total transaction of $50,306.80. Following the completion of the sale, the vice president directly owned 40,411 shares of the company's stock, valued at approximately $3,278,948.54. This represents a 1.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm's stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 26,190 shares of company stock valued at $2,269,697 over the last 90 days. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Down 1.1%

Edwards Lifesciences stock opened at $91.51 on Friday. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The company's fifty day moving average price is $88.73 and its two-hundred day moving average price is $84.37. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The company has a market capitalization of $52.69 billion, a price-to-earnings ratio of 52.59, a PEG ratio of 2.30 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the prior year, the company posted $0.67 EPS. The firm's revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source